{"id":"W2083429682","doi":"10.1097/jto.0b013e3181e77a92","title":"Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Cetuximab; Internal medicine; Oncology; Phases of clinical research; Regimen; Gastroenterology; Progression-free survival; Epidermal growth factor receptor; Adenocarcinoma; Chemotherapy; Colorectal cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00143291,0.0003424857,0.001369828,0.0006681552,0.0001387475,0.00002321245,0.0003027011,0.0001853396,0.001205639],"category_scores_gemma":[0.0001754488,0.0002219435,0.000184725,0.0004437922,0.00022016,0.0002415904,0.00009477185,0.001796882,0.00003300005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007449583,"about_ca_system_score_gemma":0.001714288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001439481,"about_ca_topic_score_gemma":0.001941433,"domain_scores_codex":[0.9966809,0.0005559257,0.001000619,0.0003874638,0.0007588246,0.0006162444],"domain_scores_gemma":[0.997445,0.0003153373,0.0007294267,0.0003987379,0.0005250094,0.0005864872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08436464,0.07997296,0.5739529,0.00007468178,0.001409667,0.02458089,0.003829027,0.000004190275,0.0004042907,0.00002889469,0.0002396905,0.2311382],"study_design_scores_gemma":[0.07128747,0.4033197,0.5198612,0.00004397756,0.0005210721,0.001489713,0.001114955,0.00001193599,0.0005476169,0.0001723131,0.001446887,0.0001831716],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949131,0.001532309,0.00001599808,0.001061483,0.0004614606,0.001552696,0.00002674199,0.00001630947,0.0004199101],"genre_scores_gemma":[0.9962419,0.00003829219,0.002424808,0.0005196677,0.0003611377,0.00007289233,0.00002658507,0.00004817062,0.0002665956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3233468,"threshold_uncertainty_score":0.9997074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03023443675054934,"score_gpt":0.4276358738198085,"score_spread":0.3974014370692592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}